Valuation : Avadel Pharmaceuticals plc

Market Cap 2.12B 1.83B 1.72B 1.57B 2.95B 203B 2.96B 20.36B 7.94B 102B 7.97B 7.8B 340B P/E 2024
-20.5x
P/E 2025 33.7x
Enterprise Value 2B 1.72B 1.61B 1.47B 2.77B 191B 2.78B 19.12B 7.46B 96.26B 7.49B 7.33B 319B EV / Sales 2024
5.78x
EV / Sales 2025 7.12x
Free-Float
99.5%
Yield 2024 *
-
Yield 2025 -

Last Transcript : Avadel Pharmaceuticals plc

1 day+0.05%
Current year+0.42%
Current year 21.4
Extreme 21.395
21.76
1 year 13.83
Extreme 13.83
23.57
3 years 6.38
Extreme 6.38
23.57
5 years 6.38
Extreme 6.38
23.57
10 years 6.38
Extreme 6.38
23.57
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 07/12/2020
Chief Tech/Sci/R&D Officer - 02/12/2019
Investor Relations Contact - -
Date Insider Type Main position Quantity % Market Cap.
2/13/26 A
Weiss Asset Management LP
SellCompany 11,112,052 11.3600%
2/12/26 A Issuer sale

Director

468,962 0.4794%
2/12/26 A Issuer sale

Chairman

407,984 0.4171%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%-.--%+48.02% - 2.12B
-0.13%-6.44%+60.47%+112.05% 1,047B
+0.85%-0.81%+52.77%+63.15% 646B
-1.03%-3.58%+22.87%+73.29% 451B
-1.46%-4.50%+37.43%+38.41% 355B
-0.72%-2.89%+21.86%+36.79% 291B
-1.19%-2.21%+1.35%+12.29% 252B
-1.05%-1.57%+51.40%+68.55% 234B
+0.08%-1.78%-17.64%-54.29% 203B
-2.14%-0.30%+29.42%+89.10% 181B
Average -0.68%-2.41%+30.80%+48.82% 366.14B
Weighted average by Cap. -0.48%-3.46%+38.67%+65.51%

Financials

2024 2025
Net sales 169M 146M 137M 125M 235M 16.16B 236M 1.62B 632M 8.16B 635M 621M 27.05B 279M 241M 226M 206M 388M 26.68B 389M 2.68B 1.04B 13.47B 1.05B 1.03B 44.65B
Net income -48.83M -42.08M -39.45M -36.01M -67.85M -4.67B -68.06M -468M -183M -2.36B -183M -179M -7.81B 64.67M 55.73M 52.25M 47.7M 89.85M 6.18B 90.14M 620M 242M 3.12B 243M 238M 10.35B
Net Debt -34.93M -30.1M -28.22M -25.76M -48.54M -3.34B -48.69M -335M -131M -1.69B -131M -128M -5.59B -129M -111M -104M -95.07M -179M -12.32B -180M -1.24B -482M -6.22B -484M -473M -20.62B
Logo Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Employees
188
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. AVDL Stock